



Company Registration No. 200404283C

Livingstone Health Holdings Limited

Unaudited Condensed Interim Financial Statements
For the six months and the full year ended 31 March 2026

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542, Telephone (65) 6232 3210.

Livingstone Health Holdings Limited

Table of content

	Page
Condensed interim consolidated statement of profit or loss and other comprehensive income	1
Condensed interim statements of financial position	2
Condensed interim statement of changes in equity	3
Condensed interim consolidated statement of cash flows	5
Notes to the condensed interim consolidated financial statements	6
Other information required by Appendix 7C of the Catalist Rules	17

Livingstone Health Holdings Limited

Condensed interim consolidated statement of profit or loss and other comprehensive income
For the six months and full year ended 31 March 2026

	Note	Group			Group		
		6 months ended		Change	12 months ended		Change
		2026	2025		2026	2025	
		S\$'000	S\$'000	%	S\$'000	S\$'000	%
Revenue	4	14,468	14,195	1.9	29,288	27,648	5.9
Other operating income		276	297	(7.1)	574	844	(32.0)
Other gain, net		-	58	NM	-	58	NM
Consumables and medical supplies used		(3,289)	(2,962)	11.0	(6,409)	(5,652)	13.4
Employee benefits expenses		(7,890)	(7,880)	0.1	(15,809)	(15,025)	5.2
Depreciation expenses		(1,178)	(1,238)	(4.8)	(2,415)	(2,526)	(4.4)
(Impairment loss on)/reversal of financial assets, net		(11)	43	NM	(34)	43	NM
Other operating expenses		(2,877)	(2,380)	20.9	(5,382)	(4,895)	9.9
Finance costs		(105)	(174)	(39.7)	(230)	(395)	(41.8)
Share of results from equity-accounted for associates		(13)	(12)	8.3	(76)	(30)	>100
(Loss)/profit before tax	5	(619)	(53)	>100	(493)	70	NM
Income tax (expense)/credit	7	88	140	(37.1)	(3)	97	NM
(Loss)/profit for the financial period/year		(531)	87	NM	(496)	167	NM
Other comprehensive (loss)/income:							
<i>Components of other comprehensive (loss)/income that will be reclassified to profit or loss, net of taxation</i>							
Exchange differences on translating foreign operations		-	-	-	-	-	-
Total comprehensive (loss)/income for the financial period/ year		(531)	87	NM	(496)	167	NM
(Loss)/profit attributable to:							
Owners of the Company		(12)	425	NM	223	557	(60.0)
Non-controlling interests		(519)	(338)	53.6	(719)	(390)	84.4
		(531)	87	NM	(496)	167	NM
Total comprehensive (loss)/income attributable to:							
Owners of the Company		(12)	425	NM	223	557	(60.0)
Non-controlling interests		(519)	(338)	53.6	(719)	(390)	84.4
		(531)	87	NM	(496)	167	NM
Earnings per share attributable to owners of the Company (cents per share)							
Basic	8	0.00	0.07	NM	0.04	0.10	(60.0)
Diluted		0.00	0.06	NM	0.03	0.08	(62.5)
Adjusted net profit/(loss) after tax (excluding Ardennes' losses and non-recurring expenses due to closure*)							
Owners of the Company		224	NA	NA	608	NA	NA
Non-controlling interests		(292)	NA	NA	(349)	NA	NA
		(68)	NA	NA	259	NA	NA

NM: Not meaningful

NA: Not applicable

* Ardennes Healthcare Pte. Ltd., which had been underperforming, had ceased operations in February 2026.

The accompanying accounting policies and explanatory notes form an integral part of the condensed interim financial statements.

Livingstone Health Holdings Limited

Condensed interim statements of financial position
As at 31 March 2026

	Note	Group		Company	
		31.03.2026 S\$'000	31.03.2025 S\$'000	31.03.2026 S\$'000	31.03.2025 S\$'000
ASSETS					
<u>Non-current assets</u>					
Property, plant and equipment	10	3,218	5,064	-	-
Goodwill arising on consolidation	12	5,571	4,165	-	-
Investments in subsidiaries		-	-	43,124	73,000
Investments in associates		469	75	-	-
Total non-current assets		9,258	9,304	43,124	73,000
<u>Current assets</u>					
Trade receivables		4,017	4,952	-	-
Other receivables		2,288	1,818	1,981	1,599
Inventories		878	876	-	-
Cash and cash equivalents		2,426	3,005	79	528
Total current assets		9,609	10,651	2,060	2,127
Total assets		18,867	19,955	45,184	75,127
EQUITY AND LIABILITIES					
<u>Equity attributable to owners of the Company</u>					
Share capital	15	26,344	26,083	72,671	72,410
Merger reserve		277	277	-	-
Other reserves		22	22	-	-
Accumulated losses		(19,746)	(19,969)	(31,386)	(1,089)
Equity attributable to owners of the Company		6,897	6,413	41,285	71,321
Non-controlling interests		(2,374)	(1,503)	-	-
Total equity		4,523	4,910	41,285	71,321
<u>Non-current liabilities</u>					
Other payables		2,999	2,742	2,450	2,450
Loans and borrowings	14	1,522	350	500	350
Lease liabilities		480	1,554	-	-
Deferred tax liabilities		-	3	-	-
Total non-current liabilities		5,001	4,649	2,950	2,800
<u>Current liabilities</u>					
Trade payables		1,779	1,852	-	-
Other payables		3,168	3,528	198	214
Contract liabilities		1,192	1,182	-	-
Loans and borrowings	14	1,443	1,689	751	792
Lease liabilities		1,548	1,975	-	-
Income tax payable		213	170	-	-
Total current liabilities		9,343	10,396	949	1,006
Total liabilities		14,344	15,045	3,899	3,806
Total equity and liabilities		18,867	19,955	45,184	75,127

The accompanying accounting policies and explanatory notes form an integral part of the condensed interim financial statements.

Livingstone Health Holdings Limited

Condensed interim statement of changes in equity
For the financial year ended 31 March 2026

Group	Share capital S\$'000	Merger reserve S\$'000	Other reserve S\$'000	Accumulated losses S\$'000	Total S\$'000	Non- controlling interests S\$'000	Total equity S\$'000
31 March 2026							
Balance as at 1 April 2025	26,083	277	22	(19,969)	6,413	(1,503)	4,910
Total comprehensive (loss)/income for the year	-	-	-	223	223	(719)	(496)
<u>Transaction with owner recognised directly in equity</u>							
Issuance of share capital	261	-	-	-	261	-	261
Disposal of a subsidiary	-	-	-	-	-	23	23
Dividends paid to non-controlling interest	-	-	-	-	-	(175)	(175)
Balance as at 31 March 2026	26,344	277	22	(19,746)	6,897	(2,374)	4,523
31 March 2025							
Balance as at 1 April 2024	24,191	57	22	(20,526)	3,744	900	4,644
Total comprehensive income/(loss) for the year	-	-	-	557	557	(390)	167
<u>Transaction with owner recognised directly in equity</u>							
Issuance of share capital	2,029	-	-	-	2,029	-	2,029
Acquisition of additional shares in subsidiaries	-	220	-	-	220	(1,883)	(1,663)
Transaction costs	(137)	-	-	-	(137)	-	(137)
Shares subscribed by non-controlling interest	-	-	-	-	-	5	5
Dividends paid to non-controlling interest	-	-	-	-	-	(135)	(135)
Balance as at 31 March 2025	26,083	277	22	(19,969)	6,413	(1,503)	4,910

The accompanying accounting policies and explanatory notes form an integral part of the condensed interim financial statements.

Livingstone Health Holdings Limited

Condensed interim statement of changes in equity
For the financial year ended 31 March 2026

Company	Share capital S\$'000	Accumulated losses S\$'000	Total equity S\$'000
31 March 2026			
Balance as at 1 April 2025	72,410	(1,089)	71,321
Loss for the year, representing total comprehensive loss for the year	-	(30,297)	(30,297)
<u>Transactions with owner recognised directly in equity</u>			
Issuance of share capital	261	-	261
Balance as at 31 March 2026	72,671	(31,386)	41,285
31 March 2025			
Balance as at 1 April 2024	70,518	(599)	69,919
Loss for the year, representing total comprehensive loss for the year	-	(490)	(490)
<u>Transactions with owner recognised directly in equity</u>			
Issuance of share capital	2,029	-	2,029
Transaction costs	(137)	-	(137)
Balance as at 31 March 2025	72,410	(1,089)	71,321

The accompanying accounting policies and explanatory notes form an integral part of the condensed interim financial statements.

Livingstone Health Holdings Limited

Condensed interim consolidated statement of cash flows For the financial year ended 31 March 2026

	Note	Group	
		12 months ended 31 March	
		2026	2025
		S\$'000	S\$'000
Cash flows from operating activities			
(Loss)/profit before tax		(493)	70
Adjustments for:			
Depreciation expense		2,415	2,526
Interest expense		230	395
Interest income		(8)	(39)
Other gain, net		-	(58)
Impairment loss on/(reversal of) financial assets, net		29	(43)
Bad debt written-off		5	14
Share of results from equity-accounted investees		76	30
Plant and equipment written-off		84	52
Loss/(gain) on disposal of property, plant and equipment		60	(7)
Operating cash inflows before changes in working capital		2,398	2,940
Changes in working capital:			
Trade receivables		982	476
Other receivables		(45)	169
Inventories		24	8
Trade payables		(73)	550
Other payables		(160)	(94)
Contract liabilities		10	20
Cash flows generated from operations		3,136	4,069
Income tax (paid)/refund		(48)	236
Net cash flows from operating activities		3,088	4,305
Cash flows from investing activities			
Acquisition of additional shares in subsidiaries, net of cash		(682)	(382)
Loans and advances to associates		(656)	(452)
Purchase of plant and equipment	10	(308)	(280)
Proceeds from disposal of plant and equipment		206	22
Investments in associates		(470)	(105)
Payment of deferred consideration		(263)	-
Interest received		8	39
Net cash flows used in investing activities		(2,165)	(1,158)
Cash flows from financing activities			
Proceeds from share issuance and exercise of warrants, net of transaction costs		19	1,487
Repayment of lease liabilities		(2,198)	(2,168)
Proceeds of interest-free loan from non-controlling interest		25	44
Proceeds from loans and borrowings		2,800	-
Repayment of loans and borrowings		(1,900)	(2,683)
Proceeds from issue of shares to non-controlling interest		-	5
Interest paid		(73)	(150)
Dividends paid to non-controlling interest		(175)	(135)
Net cash flows used in financing activities		(1,502)	(3,600)
Net decrease in cash and cash equivalents		(579)	(453)
Cash and cash equivalents at the beginning of financial year		3,005	3,458
Cash and cash equivalents at the end of financial year		2,426	3,005

1. Corporate information

Livingstone Health Holdings Limited (the "**Company**") is a limited liability company incorporated and domiciled in Singapore and listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). These condensed interim financial statements as at and for the six months and twelve months ended 31 March 2026 comprise the Company and its subsidiaries (collectively, the "**Group**").

The principal activity of the Company is that of a management consultancy service provider and an investment holding company. Through its operating member companies, the Group is engaged in the provision of medical treatment and consultancy services.

The Company is a subsidiary of Livingstone Health Consolidated Pte. Ltd. ("**LVS**") incorporated in Singapore, which is also the Company's ultimate holding company.

2. Basis of preparation

The condensed interim financial statements for the six months and twelve months ended 31 March 2026 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("**SFRS(I)**") 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last interim condensed financial statements for the financial period ended 30 September 2025.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore Dollars ("**SGD**" or "**S\$**"), which is the Company's functional currency, and all values are rounded to the nearest thousand ("**S\$'000**") except when otherwise indicated.

Figures may not add up due to rounding differences.

2.1 New and amended standards adopted by the Group

A number of amendments to standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 31 March 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

There were no significant judgements made in applying accounting policies that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next interim period.

2. Basis of preparation (cont'd)

2.2 Use of judgements and estimates (cont'd)

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following note:

- Note 12: Impairment testing of goodwill - Key assumptions underlying recoverable amounts

3. Seasonal operations

The Group's businesses are not materially affected by seasonal or cyclical factors.

4. Segment and revenue information

The Group has 3 reportable business segments, as described below, which are the Group's strategic business units. The following summary describes the operations in each of the Group's reportable business segments of Specialist Healthcare, Primary Healthcare and Others respectively.

i. Specialist Healthcare

The Specialist Healthcare segment includes services provided by healthcare professionals who focus on a specific field of medicine. This segment currently comprises (a) Anaesthesiology and Pain Management; (b) Orthopaedic Surgery; (c) Dermatology; (d) Endocrinology; (e) Colorectal and General Surgery, and this specialist suite will develop in the normal course of business as per the Group's patient needs.

ii. Primary Healthcare

The Primary Healthcare segment includes services provided by general practitioners or family physicians who are often the first point of contact of our patients. Non-exhaustively, the services here include the provision of vaccination and general medicine services that include, amongst others, the management of general acute and chronic conditions. In general, the Group's Primary Healthcare team is responsible for preventative care and disease management, and may also coordinate with specialists when necessary.

iii. Others

The Others segment is in the business of aesthetics and wellness, podiatry, nerve testing, managing healthcare solutions, consultancy functions, and provision of management services.

These operating segments are reported in a manner consistent with internal reporting provided to the Chief Operating Decision Maker ("CODM") who is also the Chief Executive Officer ("CEO"), who is responsible for allocating resources and assessing performance of the operating segments. Certain expenses, other operating income and income taxes are managed on a group basis and are not allocated to operating segments.

Livingstone Health Holdings Limited

**Notes to the condensed interim consolidated financial statements
For the financial year ended 31 March 2026**

4. Segment and revenue information (cont'd)

Based on the management reporting to the CODM, the segment assets and liabilities are not key information pertaining to financial performance of the Group that are regularly provided for his review. Therefore, the segment assets and liabilities amounts are not disclosed in the segment information.

	Specialist Healthcare S\$'000	Primary Healthcare S\$'000	Others S\$'000	Unallocated (Corporate) S\$'000	Total S\$'000
<u>6 months ended 31 March 2026</u> <u>("2H2026")</u>					
Segment revenue	8,528	4,000	1,932	8	14,468
Segment profit/(loss)	1,223	(569)	23	(1,208)	<u>(531)</u>
Depreciation	(272)	(426)	(92)	(388)	(1,178)
Share of results from equity- accounted for associates	(13)	-	-	-	(13)
Finance costs	(16)	(27)	(3)	(59)	(105)
Income tax (expense)/credit	(24)	34	4	74	88
Adjusted segment profit/(loss) (excluding Ardennes' losses and non-recurring expenses due to closure)*	1,223	(106)	23	(1,208)	(68)

* Ardennes Healthcare Pte. Ltd., which had been underperforming, had ceased operations in February 2026.

	Specialist Healthcare S\$'000	Primary Healthcare S\$'000	Others S\$'000	Unallocated (Corporate) S\$'000	Total S\$'000
<u>6 months ended 31 March 2025</u> <u>("2H2025")</u>					
Segment revenue	8,903	3,759	1,533	-	14,195
Segment profit/(loss)	1,811	(258)	(69)	(1,397)	<u>87</u>
Depreciation	(243)	(431)	(190)	(374)	(1,238)
Share of results from equity- accounted for associates	-	(12)	-	-	(12)
Finance costs	(26)	(40)	(10)	(98)	(174)
Income tax credit/(expense)	190	42	6	(98)	140

Livingstone Health Holdings Limited

Notes to the condensed interim consolidated financial statements
For the financial year ended 31 March 2026

4. Segment and revenue information (cont'd)

	Specialist Healthcare S\$'000	Primary Healthcare S\$'000	Others S\$'000	Unallocated (Corporate) S\$'000	Total S\$'000
<u>FY2026</u>					
Segment revenue	18,047	7,541	3,670	30	29,288
Segment profit/(loss)	3,217	(1,047)	10	(2,676)	<u>(496)</u>
Depreciation	(520)	(859)	(261)	(775)	(2,415)
Share of results from equity- accounted for associates	(76)	-	-	-	(76)
Finance costs	(37)	(57)	(12)	(124)	(230)
Income tax (expense)/credit	(102)	22	3	74	(3)
Adjusted segment profit/(loss) (excluding Ardennes' losses and non-recurring expenses due to closure)*	3,217	(292)	10	(2,676)	259

* Ardennes Healthcare Pte. Ltd., which had been underperforming, had ceased operations in February 2026.

	Specialist Healthcare S\$'000	Primary Healthcare S\$'000	Others S\$'000	Unallocated (Corporate) S\$'000	Total S\$'000
<u>FY2025</u>					
Segment revenue	17,530	7,042	3,076	-	27,648
Segment profit/(loss)	3,579	(348)	(110)	(2,954)	<u>167</u>
Depreciation	(488)	(842)	(450)	(746)	(2,526)
Share of results from equity- accounted for associates	-	(30)	-	-	(30)
Finance costs	(50)	(83)	(24)	(238)	(395)
Income tax (expense)/credit	(11)	62	58	(12)	97

Geographical information

The Group's operations are mainly in Singapore.

Livingstone Health Holdings Limited

**Notes to the condensed interim consolidated financial statements
For the financial year ended 31 March 2026**

4. Segment and revenue information (cont'd)

(a) Disaggregation of revenue

	Group	
	FY2026 S\$'000	FY2025 S\$'000
Specialist healthcare	18,047	17,530
Primary healthcare	7,541	7,042
Others	3,670	3,076
Unallocated (Corporate)	30	-
	<u>29,288</u>	<u>27,648</u>
Timing of revenue recognition: At a point in time	<u>29,288</u>	<u>27,648</u>

(b) A breakdown of sales

	Group		
	FY2026 S\$'000	FY2025 S\$'000	Change %
Sales reported for first half year	14,820	13,453	10.2
Operating profit after tax before deducting minority interests reported for first half year	35	80	(56.3)
Sales reported for second half year	14,468	14,195	1.9
Operating (loss)/profit after tax before deducting minority interests reported for second half year	(531)	87	NM

NM: Not meaningful

5. (Loss)/Profit before tax

The following items have been included in arriving at (loss)/profit before tax:

	Group			
	2H2026 S\$'000	2H2025 S\$'000	FY2026 S\$'000	FY2025 S\$'000
Wage and other employment credit scheme	(132)	(139)	(210)	(257)
Loss/(gain) on disposal of plant and equipment	60	(3)	60	(7)
Rental income	(120)	(175)	(290)	(334)
Interest income	(3)	(19)	(8)	(39)
Loss on remeasurement of equity interest in previously held equity interest	-	362	-	362
Reversal of impairment loss on equity interest in previously held equity interest	-	(420)	-	(420)
Marketing expenses	1,334	1,165	2,522	2,319
Rental expenses	116	6	219	75
Hospital administrative charges	221	229	510	488
Professional fees	319	282	444	525
Bank and credit card charges	174	160	352	302
Repair and maintenance	106	64	179	121
Plant and equipment written-off	79	44	84	52
Bad debts written-off	5	14	5	14
Interest expense on:				
- loans and borrowings	40	59	73	150
- lease liabilities	65	115	157	245

Livingstone Health Holdings Limited

Notes to the condensed interim consolidated financial statements For the financial year ended 31 March 2026

6. Related party transactions

In addition to the related party information disclosed elsewhere in the condensed interim financial statements, the following significant transactions between the Group and related parties took place at terms agreed between the parties during the financial year:

	2H2026 S\$'000	2H2025 S\$'000	FY2026 S\$'000	FY2025 S\$'000
Sales of services to a company related to key management personnel (Note (i))	5	26	19	28
Purchase of services from a company related to key management personnel (Note (i))	-	47	-	93
Rental paid to a company related to key management personnel (Note (ii))	125	125	251	251
Administrative income charged to an associate	38	-	76	66
Sales to associates	46	58	100	107
Other income charged to associates	-	2	-	2
Purchase of services from associates	3	-	7	-
Management fee charged to a joint venture	-	25	-	100
Sales to a joint venture	-	12	-	30
Purchase of services from a joint venture	-	-	-	1

Companies related to directors

The Group had the following transactions with companies related to key management personnel:

- (i) The Group had engaged or is being engaged by SN Orthopaedics Pte. Ltd. ("**SN Orthopaedics**"), a company that is wholly owned by Dr Ng Yung Chuan, Sean ("**Dr Sean Ng**") for medical related services. Dr Sean Ng is the brother of Mr Dax Ng Yung Sern ("**Mr Dax Ng**"), Executive Director, Chief Commercial Officer and shareholder of the Company. The Group generated S\$5,000 in 2H2026 (2H2025: S\$26,000) and S\$19,000 in FY2026 (FY2025: S\$28,000) for rendering medical services to SN Orthopaedics. The Group did not purchase any medical services for both 2H2026 and FY2026 (2H2025: S\$47,000 and FY2025: S\$93,000).
- (ii) As announced on 7 October 2024, the Group entered into a tenancy agreement with VS Investment Holdings Pte Ltd ("**VS**"), a company that is 90% owned by Dr Sean Ng and 10% owned by Dr Rachel Lim, the spouse of Dr Sean Ng, to lease commercial premises for rental in 2H2026 of approximately S\$125,000 (2H2025: S\$125,000) and in FY2026 of approximately S\$251,000 (FY2025: S\$251,000).

7. Income tax credit/(expense)

The Group calculates the period's income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense for the six months and financial year ended 31 March 2026 and 2025 are:

	2H2026 S\$'000	2H2025 S\$'000	FY2026 S\$'000	FY2025 S\$'000
Current income tax				
- current income taxation	(20)	(119)	(111)	(162)
- Over-provision in respect of previous years	105	300	105	300
	85	181	(6)	138
Deferred income tax				
- origination and reversal of temporary differences	3	(41)	3	(41)
Income tax credit/(expense)	88	140	(3)	97

Livingstone Health Holdings Limited

Notes to the condensed interim consolidated financial statements For the financial year ended 31 March 2026

8. Earnings per share

The earnings per ordinary share (basic) was calculated by dividing the net profit for the period attributable to owners of the Company by the weighted average number of ordinary shares in issue of 629,278,842 in 2H2026 (2H2025: 613,253,637) and 624,164,222 in FY2026 (FY2025: 580,046,049).

The earnings per ordinary share (on a fully diluted basis) was calculated by dividing the net profit for the period attributable to owners of the Company by the weighted average number of ordinary shares in issue of 716,569,496 in 2H2026 (2H2025: 702,284,557) and 711,794,804 in FY2026 (FY2025: 670,563,596), adjusted to take into account the dilutive effect arising from the outstanding Warrants pursuant to the Company's Rights cum Warrants Issue completed on 3 July 2024.

9. Net assets value

	<u>Group</u>		<u>Company</u>	
	<u>31.03.2026</u>	<u>31.03.2025</u>	<u>31.03.2026</u>	<u>31.03.2025</u>
Net assets value per share (cents)	1.10	1.04	6.56	11.61

Net asset value per ordinary share is calculated based on 629,348,700 and 614,315,905 outstanding as at 31 March 2026 and 31 March 2025 respectively.

10. Property, plant and equipment

During the financial year, the Group acquired plant and equipment for an aggregate of approximately S\$308,000 (FY2025: S\$1,462,000) of which none (FY2025: S\$1,182,000) was acquired by means of leases and other non-cash arrangement. The Group also disposed property, plant and equipment with an aggregate net book value of S\$266,000 (FY2025: S\$15,000).

11. Acquisitions of subsidiaries

A) Acquisition of PMG INT 2 Pte Ltd and re-named to PMG RH Pte Ltd

PMG INT 2 Pte Ltd ("**PMG INT 2**") was formerly an associate of the Group, which the Group held a 15% interest then.

On 2 February 2026, the Group's 100% owned subsidiary, Phoenix Medical Group Pte Ltd. ("**PMG**"), acquired all the shares of PMG INT 2 and increased its shareholding of the issued share capital of PMG INT 2 from 15% to 100%. PMG INT 2 was also re-named to PMG RH Pte Ltd ("**PMG RH**") on 3 February 2026. The consideration of S\$3,126 was negotiated at arm's length and on a willing-buyer willing-seller basis, after taking into account the unaudited net assets of the PMG INT 2 as at 31 January 2026.

Details of the recognition of the consideration paid, the assets acquired and liabilities recognised, and the effects on the cash flows of the Group, at the acquisition date, are as follows:

a. Assets and liabilities recognised as a result of the acquisition

Assets	S\$'000
Property, plant and equipment	185
Trade and other receivables	46
Inventory	23
Cash and cash equivalents	34
	<hr/>
	288

Livingstone Health Holdings Limited

**Notes to the condensed interim consolidated financial statements
For the financial year ended 31 March 2026**

Liabilities	
Trade and other payables	446
Lease liabilities	114
	<u>560</u>
Net identifiable liabilities	<u>272</u>
b. Consideration and goodwill	S\$'000
Cash paid	3
Add: Fair value of net identifiable liabilities	272
Goodwill arising on acquisition	<u>275</u>
c. Net cash inflow arising from the acquisition	S\$'000
Cash paid	(3)
Add: Cash and cash equivalents acquired	34
Net cash inflow from acquisition	<u>31</u>

B) Acquisition of Wellington Pte. Ltd.

On 4 March 2026, the Group's 100% owned subsidiary, PMG, completed the acquisition of 100% of the total issued share capital of Wellington Pte. Ltd. ("**Wellington**") for S\$1,330,000, subject to deferred consideration adjustments (if any). Wellington operates a general practice clinic offering medical services located at 104 Hougang Ave 1 #01-1123, Singapore 530104. Wellington has an issued and paid-up capital of S\$1,000 comprising 1,000 ordinary shares.

Details of the recognition of the consideration paid, the assets acquired and liabilities recognised, and the effects on the cash flows of the Group, at the acquisition date, are as follows:

a. Assets and liabilities recognised as a result of the acquisition	S\$'000
Assets	
Property, plant and equipment	NM*
Trade and other receivables	70
Inventory	3
Cash and cash equivalents	20
	<u>93</u>
Liabilities	
Trade and other payables	15
Income tax payables	84
	<u>99</u>
Net identifiable liabilities	<u>6</u>

*NM: Not meaningful, less than S\$1,000

b. Consideration and goodwill	S\$'000
Cash paid	699
Deferred consideration	426
Add: Fair value of net identifiable liabilities	6
Goodwill arising on acquisition	<u>1,131</u>

Livingstone Health Holdings Limited

**Notes to the condensed interim consolidated financial statements
For the financial year ended 31 March 2026**

c. Net cash outflow arising from the acquisition

	S\$'000
Cash paid	(699)
Add: Cash and cash equivalents acquired	20
Net cash outflow from acquisition	<u>(679)</u>

12. Goodwill arising on consolidation

Goodwill acquired through business combinations is allocated to the cash-generating units ("CGU") that are expected to benefit from the business combination. The Group evaluates the CGU for impairment annually, or more frequently when there is an indication for impairment.

The carrying amount of goodwill has been allocated to the CGU in the reportable segments as follows:

<u>Group</u>	Primary Healthcare S\$'000	Specialist Healthcare S\$'000	Others S\$'000	Total S\$'000
At 1 April 2025	989	2,647	529	4,165
Arising on acquisition	1,406	-	-	1,406
At 31 March 2026	<u>2,395</u>	<u>2,647</u>	<u>529</u>	<u>5,571</u>

Management is of the view that any reasonable possible change in any of the above key assumptions are not likely to materially cause the CGU's carrying amount to exceed its recoverable amount.

13. Financial assets and financial liabilities

	<u>Group</u>		<u>Company</u>	
	31.03.2026	31.03.2025	31.03.2026	31.03.2025
	S\$'000	S\$'000	S\$'000	S\$'000
Financial assets				
Financial assets at amortised cost:				
- Trade receivables	4,017	4,952	-	-
- Other receivables excluding prepayments and GST receivable	1,961	1,517	1,950	1,567
- Cash and cash equivalents	2,426	3,005	79	528
	<u>8,404</u>	<u>9,474</u>	<u>2,029</u>	<u>2,095</u>
Financial liabilities				
Financial liabilities at amortised cost:				
- Trade payables	1,779	1,852	-	-
- Other payables and accruals*	5,350	5,474	2,594	2,608
- Lease liabilities	2,028	3,529	-	-
- Loans and borrowings	2,965	2,039	1,251	1,142
	<u>12,122</u>	<u>12,894</u>	<u>3,845</u>	<u>3,750</u>

* Excluding GST payable, provision for unutilised leave and provision for reinstatement cost

Livingstone Health Holdings Limited

**Notes to the condensed interim consolidated financial statements
For the financial year ended 31 March 2026**

14. Loans and borrowings

	<u>Group</u>		<u>Company</u>	
	31.03.2026 S\$'000	31.03.2025 S\$'000	31.03.2026 S\$'000	31.03.2025 S\$'000
<u>Amounts repayable within one year</u>				
Secured	1,413	1,615	751	792
Unsecured	30	74	-	-
<u>Amounts repayable after one year</u>				
Secured	1,453	350	500	350
Unsecured	69	-	-	-
	<u>2,965</u>	<u>2,039</u>	<u>1,251</u>	<u>1,142</u>

Total loans and borrowings amounted to S\$2,866,000 (FY2025: S\$1,965,000) are secured by guarantee from the Company and its subsidiaries.

15. Share capital

<u>Group</u>	<u>31.03.2026</u>		<u>31.03.2025</u>	
	<u>Number of shares '000</u>	<u>S\$'000</u>	<u>Number of shares '000</u>	<u>S\$'000</u>
<u>Issued and fully paid ordinary shares:</u>				
Beginning of year	614,316	26,083	491,949	24,191
Issue of new ordinary shares				
- Share placement	-	-	-	-
- Rights cum Warrants Issue	-	-	93,264 ^{#1}	1,492
- Acquisition of 49% in Phoenix Medical Group	14,285 ^{#4}	242	23,808 ^{#2}	405
- Exercise of Warrants	748 ^{#5}	19	5,295 ^{#3}	132
Transaction costs	-	-	-	(137)
At the end of financial year	<u>629,349</u>	<u>26,344</u>	<u>614,316</u>	<u>26,083</u>
<u>Company</u>	<u>31.03.2026</u>		<u>31.03.2025</u>	
	<u>Number of shares '000</u>	<u>S\$'000</u>	<u>Number of shares '000</u>	<u>S\$'000</u>
<u>Issued and fully paid ordinary shares:</u>				
Beginning of year	614,316	72,410	491,949	70,518
Issue of new ordinary shares				
- Share placement	-	-	-	-
- Rights cum Warrants Issue	-	-	93,264 ^{#1}	1,492
- Acquisition of 49% in Phoenix Medical Group	14,285 ^{#4}	242	23,808 ^{#2}	405
- Exercise of Warrants	748 ^{#5}	19	5,295 ^{#3}	132
Transaction costs	-	-	-	(137)
At the end of financial year	<u>629,349</u>	<u>72,671</u>	<u>614,316</u>	<u>72,410</u>

^{#1} On 3 July 2024, the Company completed its Rights cum Warrants Issue and allotted and issued 93,263,938 new ordinary shares and 93,263,938 free detachable and unlisted Warrants. The issue price was S\$0.016 for each Rights Share subscription. The net proceeds raised from the Rights cum Warrants Issue was approximately S\$1.38 million, after deducting costs and expenses of approximately S\$0.11 million incurred in connection with the issuance.

Livingstone Health Holdings Limited

Notes to the condensed interim consolidated financial statements For the financial year ended 31 March 2026

- #2 On 1 August 2024, Livingstone Health Ltd., a wholly-owned subsidiary of the Company had completed the acquisition of the remaining 49% of the total issued share capital of Phoenix Medical Group Pte Ltd for a consideration of S\$1,585,640, comprising S\$776,160 in cash and an issuance of 47,616,465 ordinary shares of the company (“**Consideration Shares**”) at an issue price of S\$0.017 per Consideration Share. Pursuant to the Acquisition Agreement, a portion of the Consideration Shares, comprising 23,808,233 new ordinary shares of the Company were allotted and issued on 1 August 2024.
- #3 During FY2025, the Company had allotted and issued an aggregate of 5,295,286 new ordinary share in the share capital of the Company pursuant to the exercise of Warrants by the Warrantheholders. Each Warrant entitles the Warrantheholder to subscribe for one new ordinary share in the share capital of the Company at an exercise price of S\$0.025 for each new share. The net proceeds raised from the exercise of warrants was approximately S\$0.13 million.
- #4 On 1 August 2025, the Company had allotted and issued an aggregate of 14,284,939 new ordinary share in the share capital of the Company in relation to the deferred consideration shares pursuant to the acquisition of the remaining 49% of the total issued share capital of Phoenix Medical Group Pte Ltd.
- #5 During FY2026, the Company had allotted and issued an aggregate of 747,856 new ordinary share in the share capital of the Company pursuant to the exercise of Warrants by the Warrantheholders. Each Warrant entitles the Warrantheholder to subscribe for one new ordinary share in the share capital of the Company at an exercise price of S\$0.025 for each new share. The net proceeds raised from the exercise of warrants was approximately S\$19,000.

The Company does not hold any treasury shares in the Company as at 31 March 2026 and 31 March 2025.

The Company’s subsidiaries do not hold any shares in the Company as at 31 March 2026 and 31 March 2025.

As at 31 March 2026, there were 87,220,796 outstanding Warrants that can be exercised into 87,220,796 ordinary shares (31 March 2025: 87,968,652). Save for the outstanding Warrants, there are no outstanding convertibles as at 31 March 2026 and 31 March 2025.

16. Subsequent events

There are no known subsequent events which have led to adjustments to this set of financial statements.

Other Information Required by Appendix 7C of the Catalist Rules

Livingstone Health Holdings Limited

Other information required by Appendix 7C of the Catalyst Rules For the financial year ended 31 March 2026

1. Review

The condensed interim statements of financial position of Livingstone Health Holdings Limited (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) as at 31 March 2026 and the related condensed interim consolidated statement of profit or loss and other comprehensive income, condensed interim statement of changes in equity and condensed interim consolidated statement of cash flows for the six months and financial year ended and certain explanatory notes have not been audited or reviewed by the Company’s auditors.

1A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

- (a) Updates on the efforts taken to resolve each outstanding audit issue.
- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable. The Company’s latest audited financial statements for the financial year ended 31 March 2025 were not subjected to any adverse opinion, qualified opinion or disclaimer of opinion.

2. Review of performance of the Group

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (FY2026 vs FY2025)

The Group’s revenue increased by 5.9% from S\$27.6 million in FY2025 to S\$29.3 million in FY2026, mainly attributable to higher revenues contribution across all business segments: Specialist Healthcare (increased by S\$0.5 million or 2.9% compared to FY2025), Primary Healthcare (increased by S\$0.5 million or 7.1% compared to FY2025), and Others (increased by S\$0.6 million or 19.3% compared to FY2025).

Other operating income decreased by S\$0.3 million to S\$0.6 million in FY2026 mainly due to (i) lower rental income, (ii) lower government grants received in relation to wage credit schemes, (iii) lower interest income and iv) lower other miscellaneous income.

Consumables and medical supplies used increased by S\$0.8 million or 13.4% to S\$6.4 million in FY2026 in line with higher revenue.

Employee benefits expenses increased by S\$0.8 million to S\$15.8 million in FY2026 mainly due to (i) the expansion of Primary Healthcare clinical team and (ii) higher variable bonuses.

Depreciation expenses decreased by S\$0.1 million to S\$2.4 million in FY2026 mainly due to lower depreciation expenses of the rights of use assets upon early termination of a lease by the aesthetics business.

The Group recorded an expected credit loss of S\$34,000 in FY2026, compared to a net bad debt recovery of approximately S\$43,000 in FY2025.

Other operating expenses, given increased business activities and revenue base, increased by S\$0.5 million to S\$5.4 million in FY2026. The increase was mainly attributable to the increases in (i) marketing expenses of S\$0.2 million, (ii) rental expenses of S\$0.1 million, (iii) loss of approximately S\$60,000 on disposal of fixed assets due to closure of Ardennes Healthcare Pte. Ltd. (“**Ardennes**”), and (iv) general operating expenses of S\$0.1 million.

Finance costs decreased by S\$0.2 million to S\$0.2 million in FY2026 due mainly to lower interest expenses for bank borrowings and hire purchases, and lower expenses for lease liabilities.

Livingstone Health Holdings Limited

Other information required by Appendix 7C of the Catalyst Rules For the financial year ended 31 March 2026

Share of losses from the Group's investment in associates increased by S\$46,000 mainly due to its 20% investment in The Metabolic Clinic, the endocrinology clinic that commenced operations in June 2025.

The Group recorded a net income tax expense of S\$3,000 in FY2026 as compared to a net income tax credit of S\$0.1 million in FY2025, mainly due to lower income tax refunds arising from excess tax payments in prior year as the Group utilised group tax relief.

As a result of the above, the Group recorded a net profit attributable to owners of the Group ("**Net Profit**") of S\$0.2 million in FY2026, compared to S\$0.6 million in FY2025.

Excluding the losses and non-recurring expenses relating to the discontinued Ardennes, the Group's adjusted Net Profit for FY2026 would have been approximately S\$0.6 million.

Condensed Interim Statements of Financial Position (31 March 2026 vs 31 March 2025)

Current assets decreased by S\$1.0 million to S\$9.6 million as at 31 March 2026 mainly due to the decrease in (i) cash and cash equivalents of S\$0.6 million and (ii) trade and other receivables of S\$0.4 million, as explained in the review of cash flow statements.

Current liabilities decreased by S\$1.1 million to S\$9.3 million as at 31 March 2026 mainly due to (i) the decrease of S\$0.4 million in lease liabilities, (ii) the decrease of S\$0.2 million in loans and borrowings due to repayments, (iii) reduction of S\$0.4 million in other payables due to the payment and settlement of the deferred consideration pursuant to the acquisition of 49% of Phoenix Medical Group ("**PMG**") (as announced on 15 July 2024) and (iv) a decrease of S\$0.1 million in trade payables.

As at 31 March 2026, non-current assets decreased slightly by S\$46,000 to S\$9.3 million mainly due to the decrease of property, plant and equipment of S\$1.8 million as a result of (i) sale of assets and write-off of assets arising from Ardennes' closure, (ii) rights of use assets de-recognition due to the early termination of a lease by the aesthetics business and (iii) reduced carrying amount of the rights of use assets due to depreciation, offset against an increase in goodwill of S\$1.4 million arising from the acquisition of PMG INT 2 Pte Ltd ("**PMG INT 2**") and Wellington Pte Ltd ("**Wellington**") and an increase in investment in associate of S\$0.4 million for the 20% investment in Affinity Surgery Center Pte Ltd ("**Affinity Surgery**"), a colorectal and general surgery practice.

Non-current liabilities increased by S\$0.4 million to S\$5.0 million as at 31 March 2026, mainly due to (i) an increase of S\$1.2 million in loans and borrowings from additional loan draw downs and (ii) a net increase of S\$0.3 million in other payables arising from the deferred consideration payable for the acquisition of 100% of Wellington and offset against the payment and settlement of the deferred consideration pursuant to the acquisition of 49% of PMG. The lease liabilities decreased by S\$1.1 million due to continuous lease payments.

The share capital increased by S\$0.3 million mainly due to new share issuance in relation to the deferred consideration shares for the acquisition of PMG and proceeds raised arising from the exercise of warrants. Please refer to Note 15 of the condensed interim financial statements for details of movements in share capital.

Due to the recent acquisitions completed and investments as disclosed above, the Group recorded a net debt position of S\$0.5 million as at 31 March 2026, compared to a net cash position of S\$1.0 million as at 31 March 2025.

Condensed Consolidated Statement of Cash Flows (FY2026 vs FY2025)

Net cash generated from operating activities of S\$3.1 million was mainly derived from total operating cash flows before working capital changes of S\$2.4 million, net working capital inflow of S\$0.7 million and overall net income tax paid of approximately S\$48,000.

Livingstone Health Holdings Limited

Other information required by Appendix 7C of the Catalyst Rules For the financial year ended 31 March 2026

Net cash used in investing activities amounted to S\$2.2 million which were mainly attributable to (i) net cash payment for the acquisition of Wellington and PMG INT 2 of S\$0.7 million, (ii) loans and advances to the Group's associates of S\$0.7 million, (iii) purchase of plant and equipment of S\$0.3 million, (iv) investment in associates of S\$0.5 million for Affinity Surgery (v) cash payment of S\$0.3 million for the deferred consideration; partially offset by proceeds from disposal of plant and equipment of approximately S\$0.2 million and interest income of approximately S\$8,000.

Net cash used in financing activities amounted to S\$1.5 million, mainly attributable to (i) repayment of lease liabilities of S\$2.2 million; (ii) repayment of loans and borrowings of S\$1.9 million; (iii) interest expense payment of S\$73,000 (iv) dividends paid to non-controlling interest of S\$0.2 million; partially offset by net proceeds of S\$2.8 million received from loan draw downs, S\$19,000 of proceeds from the exercise of warrants and the receipt of S\$25,000 shareholder's loan from a non-controlling interest business partner of Fidelity Neuroscience Pte. Ltd.

As a result of the above, the Group's cash and cash equivalents decreased by S\$0.6 million to S\$2.4 million as at 31 March 2026.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No specific forecast or prospect statement had been previously disclosed to shareholders.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months

During the year, the Group closed the underperforming Ardennes health screening centre, as part of the Group's strategic decision in rationalising its operations while optimising its healthcare network, to further improve its operational efficiency.

The Group will continue to invest in and focus on retaining its medical doctors and healthcare talent base, which has been instrumental in sustaining the Group's revenue growth. The Group also invested in an endocrinology specialist clinic, and a colorectal and general surgery clinic, as announced in April 2025 and December 2025 respectively. In March 2026, the Group acquired another primary care clinic after expanding its PMG network over the last two financial years. These initiatives aim to further enhance its healthcare ecosystem through broader patient outreach and enhanced cross-referral networks across its various medical disciplines while monitoring its supply chain related costs.

Due to the on-going geopolitical tensions and inflationary pressures, the Group remains cautious of the business outlook as the operating environment continues to be challenging with rising business costs.

In FY2026, the Group secured additional term loan facilities from two regional banks amounting to an aggregate of S\$4.0 million, increasing its total available banking facilities to S\$7.0 million, which could support the Group's potential acquisition opportunities and working capital requirements.

Livingstone Health Holdings Limited

Other information required by Appendix 7C of the Catalist Rules For the financial year ended 31 March 2026

5. Dividend information

(a) **Whether an interim (final) ordinary dividend has been declared (recommended); and**

No dividend has been declared or recommended for the current financial period.

(b) **Corresponding period of the immediately preceding financial year.**

No dividend has been declared or recommended for the corresponding period of the immediately preceding financial year.

(c) **Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).**

Not applicable.

(d) **The date the dividend is payable.**

Not applicable.

(e) **The date on which Registrable Transfers received by the company (up to 5.00 p.m.) will be registered before entitlements to the dividend are determined.**

Not applicable.

6. **If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision**

No dividend has been declared or recommended for the current financial year as it is deemed appropriate to conserve cash for working capital and future expansion plans.

7. **Interested person transactions**

As announced on 4 October 2024, the Group had entered into a lease agreement with VS Investment Pte. Ltd. (“VS”), which is 90% owned by Dr Sean Ng (brother of Mr Dax Ng who was appointed as a director of the Company on 8 July 2024) and 10% owned by Dr Lim Pang Yen Rachel, the spouse of Dr Sean Ng. Under the Tenancy Agreement, the premises occupy a floor area of 552 square feet. The lease term commenced on 7 October 2024 and will end on 31 October 2026. The rental rate of S\$20,320 per month (before goods and services tax) was arrived at after negotiations between the Group and VS, and is within the range of market rental values presented in the independent valuation report prepared by the independent valuer, Future Asia Advisory Pte Ltd. In addition to the rental, VS will charge the Group service charges for the upkeep and maintenance of the common areas, the operation of services supplied to and used in the building in which the premises are located, as well as fees for cleaning services and equipment on a monthly basis. The total amount of lease payments made in FY2026 was approximately S\$251,000.

Save as disclosed above, the Group has not obtained a general mandate from shareholders for interested person transactions and there are no other interested person transactions of S\$100,000 and above entered into in FY2026.

Livingstone Health Holdings Limited

Other information required by Appendix 7C of the Catalist Rules For the financial year ended 31 March 2026

8. Use of Proceeds from the Rights cum Warrants Issue

The status of the use of the net proceeds from the Rights cum Warrants issue completed on 3 July 2024 as at the date of this announcement is as follows:

Intended use of net proceeds	Balance brought forward ⁽¹⁾ (S\$'000)	Additional proceeds from Warrant exercises ⁽²⁾ (S\$'000)	Re-allocation ⁽³⁾ (S\$'000)	Amount utilised ⁽³⁾ (S\$'000)	Balance (S\$'000)
General working capital purpose	-	19	(19)	-	-
Business expansion, including acquisition	303	-	19	(322)	-
Total	303	19	-	(322)	-

Notes:

(1) Balance of the unutilised amount brought forward from 14 July 2025, as at the date of the published FY2025 annual report.

(2) Arising from the exercise of an aggregated 747,856 Warrants announced on 14 October 2025 and 17 November 2025 at the Exercise of S\$0.025 per share.

(3) Relates to acquisition of 20% Affinity Surgery Centre Pte. Ltd.

Save for the re-allocation as presented in the table, the use of the net proceeds from the Rights cum Warrants Issue disclosed above is in accordance with the intended use as disclosed in the Company's Offer Information Statement dated 11 June 2024.

The Company will provide periodic announcements on the utilisation of the fundraising proceeds as and when such proceeds are materially disbursed or utilised, and whether such use is in accordance with the stated use.

9. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H of the Catalist Rules) under Rule 720(1) of the Catalist Rules

The Company confirmed that it has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H of the Catalist Rules) under Rule 720(1) of the Catalist Rules.

10. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the operating segments.

Refer to paragraph 2 of this section for details.

11. Disclosures of incorporation, acquisition or sale of shares in subsidiaries and/or associated companies pursuant to Rule 706A of the Catalist Rules

2H2026

a) Investment in an associate company, Affinity Surgery Centre Pte. Ltd.

On 1 December 2025, the Group completed the strategic investment of 20% of the total issued share capital of Affinity Surgery Centre Pte. Ltd. ("**Affinity Surgery**") for S\$470,000. Helmed by Dr. Chen Chung Ming, Affinity Surgery provides a wide range of services to diagnose and carry out specialised treatments for conditions ranging from lumps and bumps, piles and perianal related, hernia, liver, gallstones, abdominal related and thyroid related surgeries. Other services include gastroscopy, colonoscopy screening and cancer screening. Accordingly, Affinity Surgery is a 20% indirect associated company of the Group. Please refer to the announcements dated 21 November 2025 and 1 December 2025 for further information.

b) De-consolidation of VirtueMed Pte. Ltd. and re-named to Allied Health Partners Pte. Ltd.

On 5 December 2025, VirtueMed Pte. Ltd. ("**VMPL**"), formerly a 51%-owned subsidiary of the Group, was de-consolidated and renamed to Allied Health Partners Pte. Ltd. ("**AHP**"). As VMPL had been dormant for some time and pending the development of a business plan, the Group transferred its 2% shares to its business partner for S\$1 on 5 December 2025. Since 31 March 2025, AHP's paid up capital of S\$100 remained unchanged as at 31 March 2026. Following the de-consolidation, AHP is a 49% indirect associated company of the Group.

c) Acquisition of PMG INT 2 Pte Ltd and re-named to PMG RH Pte Ltd

PMG INT 2 Pte Ltd ("**PMG INT 2**") was formerly an associate of the Group, which the Group held a 15% interest then.

On 2 February 2026, the Group's 100% owned subsidiary, Phoenix Medical Group Pte Ltd. ("**PMG**"), acquired all the shares of PMG INT 2 and increased its shareholding of the issued share capital of PMG INT 2 from 15% to 100%. PMG INT 2 was also re-named to PMG RH Pte Ltd ("**PMG RH**") on 3 February 2026. Accordingly, PMG RH became a wholly owned subsidiary of the Group.

Please refer to section 11 of the Notes to the condensed interim consolidated financial statements for FY2026 for further information.

d) Acquisition of Wellington Pte. Ltd.

On 2 March 2026, the Group's 100% owned subsidiary, PMG, completed the acquisition of 100% of the total issued share capital of Wellington Pte. Ltd. ("**Wellington**"). Accordingly, Wellington became a wholly owned subsidiary of the Group.

Please refer to section 11 of the Notes to the condensed interim consolidated financial statements for FY2026 and the announcements dated 19 February 2026 and 4 March 2026 for further information.

e) Striking off of 2 wholly owned subsidiaries, Venture Investment Pte Ltd and Atlas Physiotherapy Pte Ltd

Venture Investment Pte Ltd ("**VIPL**") is the investment holding company of Atlas Physiotherapy Pte Ltd ("**APPL**") and both entities are 100% wholly owned subsidiaries of the Group. As an investment holding company, VIPL had not carried out any business activities since incorporation, while APPL had not carried out any business activities since FY2025.

Livingstone Health Holdings Limited

Other information required by Appendix 7C of the Catalist Rules For the financial year ended 31 March 2026

The application to strike off its 2 wholly owned subsidiaries VIPL and APPL was submitted to the Accounting and Corporate Regulatory Authority on 18 December 2025 and 30 January 2026 respectively (the “**Strike-Offs**”). Both Strike-Offs were completed and VIPL and APPL were officially removed from the Register of Companies effective from 22 March 2026 and 13 May 2026 respectively.

The Strike-Offs did not have any material impact on the consolidated net tangible assets per share and consolidated earnings per share of the Group for the current financial year ending 31 March 2026. None of the Directors or controlling shareholders of the Group has any interest, direct or indirect, in both entities and the Strike-Offs, save for their interest by virtue of the Group’s interest in the two entities and the Directors’ directorships in the two entities.

12. A breakdown of the total amount of dividend (in dollar value) for the issuer’s latest full year and its previous full year

Not applicable.

13. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) of the Catalist Rules in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family relationship with director	Current position and duties, and the year the position was first held	Details of changes in duties and position held, if any, during the year
Dr Lim Pang Yen Rachel	45	Sister-in-law of Mr Dax Ng, Executive Director of the Company	Executive Officer and Head of Aesthetics and Wellness. Main duties include overseeing the aesthetics and wellness business and a practicing doctor.	No change.

On behalf of the Board of Directors

Dr Wilson Tay Ching Yit
Executive Director and Chief Executive Officer

Dax Ng Yung Sern
Executive Director and Chief Commercial Officer

Singapore
26 May 2026